^†OncoSil™ is indicated for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.³ It has been designated a breakthrough device for this indication in both the United States (FDA) and Europe (BSI).^1,2

Read more

REFERENCES 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020. 3. OncoSil™ System Instructions for Use EMEA.

OncoSil^TM has received CE Marking approval from the British Standards Institute for its use in the treatment of unresectable locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy, providing marketing authorisation in both the EU and the UK.²

Read more

REFERENCES 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020. 3. OncoSil™ System Instructions for Use EMEA.

OncoSil Medical is an innovative Australian medical technology company focused on interventional oncology. We’re passionate about improving outcomes for people with cancer. We believe it’s time to change the conversation around cancers with poor prognoses and transform the approach to their treatment.

Read more

REFERENCES 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020. 3. OncoSil™ System Instructions for Use EMEA.